According to a study published online in Diabetes Care on April 11, fast-acting insulin aspart (faster aspart) improved blood glucose control in patients with Type 1 diabetes, as compared to the conventional formulation of the drug, insulin aspart (IAsp). In the United States, insulin aspart is better known as Novo Nordisk's insulin Novolog. In many other countries, it is known as NovoRapid.